How Much Does Wegovy Cost in 2026? Cash Price, Insurance Copay Ranges, and Cheaper Alternatives

Key Takeaways (highlighted box)

• Wegovy list price is $1,349.02 per package (pen or pill) as listed by NovoCare in September 2026; Novo Nordisk has announced a $675 list price effective January 1, 2027.
• Retail cash price without any offer averages about $1,643 per month according to GoodRx (September 2026), but almost no self-pay patient needs to pay it.
• Novo's self-pay pricing as of September 4, 2026: Wegovy pen $199 a month for the first two fills (new patients, through December 31, 2026) then $349; Wegovy HD 7.2 mg $399; Wegovy pill $149 to $299 by dose.
• With commercial insurance plus the Wegovy Savings Card, eligible patients can pay as little as $25 per fill.
• Compounded semaglutide had a month-1 median of $197 (range $88 to $299 across 14 providers) in the FormBlends price index on September 3, 2026.

The short answer

Wegovy costs $1,349.02 per month at list price, about $1,643 at retail without an offer, $199 to $349 a month for the pen through Novo Nordisk's self-pay program (pill $149 to $299), and as little as $25 with commercial insurance plus the savings card. Since July 1, 2026, eligible Medicare patients pay $50 a month through the Medicare GLP-1 Bridge. Compounded semaglutide is the most common cheaper alternative, with a September 2026 median of $197 for the first month.

Table of contents

1. The 30-second answer
2. The Wegovy list price and how list pricing works
3. Retail pharmacy cash prices (Walmart, CVS, Costco, others)
4. With insurance: real copay scenarios
5. The NovoCare Pharmacy direct-ship cash price
6. The Wegovy Savings Card path to $25
7. Why Medicare and Medicaid patients pay more
8. The compounded semaglutide alternative
9. Wegovy vs Zepbound vs Ozempic on price
10. How to lower your specific Wegovy cost in 2026
11. Pill vs pen self-pay prices, September 2026
12. Medicare GLP-1 Bridge: $50 a month
13. Current savings card math
14. Annual cost scenarios
15. January 2027: the $675 list price
16. PAP income limits, 2026
17. FAQ
18. Sources
19. Footer disclaimers

The Wegovy list price and how list pricing works

Wegovy's wholesale acquisition cost (WAC) in 2026 is $1,349.02 per 28-day supply. This applies across all five doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) because Novo Nordisk prices the medication at parity regardless of strength.

The list price is what wholesalers pay Novo Nordisk before any rebates. The price you see at the pharmacy is the list price plus pharmacy markup minus any insurance-negotiated discount or savings card application.

Three reasons real prices differ from list:

1. Pharmacy benefit managers (PBMs) negotiate rebates with Novo Nordisk. A plan with a strong rebate gets a lower per-script cost than the list price; the savings flow back to the plan and partly to the patient as a lower copay.
2. Retail pharmacies add a small dispensing fee of $5 to $25 to the list price for cash-pay customers.
3. Manufacturer programs (savings card, NovoCare cash, Patient Assistance Program) reduce the price for specific eligible patients.

NovoCare lists both the Wegovy pen and the Wegovy pill at $1,349.02 per package as of September 2026. On February 24, 2026 Novo Nordisk announced that the list price of Wegovy (pen and pill), Ozempic and Rybelsus will drop to $675 a month on January 1, 2027, per CNBC.

Retail pharmacy cash prices (Walmart, CVS, Costco, others)

If you walk into a retail pharmacy with a Wegovy prescription, no insurance and no Novo self-pay offer, here is the range this table has tracked (GoodRx put the average retail price at about $1,643 in September 2026). Ask any of these pharmacies to run Novo's self-pay offer instead; see the September 2026 section below.

Pharmacy	Wegovy cash price (28-day supply)	With GoodRx coupon
Walmart	$1,330 to $1,425	$1,275 to $1,360
CVS	$1,355 to $1,450	$1,290 to $1,380
Walgreens	$1,360 to $1,460	$1,295 to $1,390
Costco (members only)	$1,295 to $1,365	Built into price
Sam's Club (members only)	$1,310 to $1,380	$1,260 to $1,330
Mark Cuban Cost Plus Drugs	Does not carry brand-name Wegovy	N/A

Costco is consistently the lowest cash price among the major chains, which is the same pattern as Ozempic and most other brand-name medications. Membership ($60 per year base, $120 executive) usually pays for itself within one Wegovy fill for cash patients.

GoodRx coupons stack with cash payments but cannot combine with insurance. If your insurance copay is higher than the GoodRx price (rare for Wegovy, but possible on a high-deductible plan), you can choose to pay the GoodRx price instead, but the spend will not count toward your deductible.

With insurance: real copay scenarios

Commercial insurance coverage of Wegovy is more restrictive than Ozempic because Wegovy is FDA-approved only for chronic weight management. In a 2026 survey of 307 employers reported by healthinsurance.org, 36 percent covered GLP-1s for weight loss and 60 percent covered them for diabetes.

Real plan scenarios from anonymized patient data:

Scenario 1: Employer PPO with anti-obesity medication coverage. Patient has BlueCross BlueShield through an employer that opted into AOM coverage. Wegovy on Tier 3. Copay $75 per fill after $1,500 deductible met. With Wegovy Savings Card: $25 per fill. Annual cost: roughly $300 plus deductible.

Scenario 2: Employer plan that excludes anti-obesity medications. Patient has UnitedHealthcare through an employer that excluded all weight-loss medications from formulary. Wegovy denied entirely. PA appeal denied. Annual cost if buying retail: $16,000-plus. Patient switched to compounded semaglutide at $239 per month ($2,868 per year).

Scenario 3: Marketplace silver plan. Patient has Healthcare.gov silver plan through Aetna. Wegovy on Tier 4 with 30% coinsurance after $5,000 deductible. Until deductible met, patient pays full negotiated rate ($1,180). After deductible met, copay drops to $354. With savings card: $129. Annual cost: highly deductible-dependent.

Scenario 4: High-deductible health plan with HSA. Patient has HDHP through small employer with $4,500 deductible. First two fills are full retail ($1,400 each). Once deductible met, $40 copay. Savings card brings to $25. Annual cost: roughly $3,100 plus.

Scenario 5: Self-employed, ACA bronze plan. Patient on bronze plan with $7,500 deductible and Wegovy on Tier 4. Effectively no coverage for Wegovy until deductible met. Novo self-pay ($199 for the first two pen fills, then $349) is cheaper than running through insurance for the first half of the year. Annual cost using self-pay for a new patient: $3,888.

The lesson from these scenarios: "How much does Wegovy cost" with insurance is highly plan-specific. A test claim at a pharmacy before you fill prevents most cost surprises.

The NovoCare Pharmacy direct-ship cash price

NovoCare Pharmacy is Novo Nordisk's direct-to-patient cash program for Wegovy patients without coverage. Launched in March 2025.

Pricing (NovoCare Price Guide dated April 2026, confirmed on wegovy.com September 4, 2026):

• $199 a month for the first two fills of the 0.25 mg and 0.5 mg starter pens, new patients only, through December 31, 2026
• $349 a month for every pen dose from 0.25 mg through 2.4 mg after the intro offer, and $399 a month for Wegovy HD 7.2 mg
• Wegovy pill: $149 a month for 1.5 mg, $199 for 4 mg (the $149 offer on 4 mg ended August 31, 2026), $299 for 9 mg and 25 mg

Eligibility:

• Must be a self-pay patient (no insurance, or insurance does not cover Wegovy)
• U.S. resident with U.S. mailing address
• Active prescription from a licensed U.S. provider

How it works:

• Patient receives prescription and orders through NovoCare or a partner platform
• NovoCare ships the Wegovy pen directly to the patient's address
• No insurance involved; simple flat monthly cash price

What NovoCare cash does NOT do:

• It does not lower price to $25.
• It does not stack with the Wegovy Savings Card.
• It does not count toward your insurance deductible (because no claim is filed).

For a cash-pay patient who wants brand-name Wegovy, the Novo self-pay price ($199 for the first two pen fills, then $349, or $149 to $299 for the pill) is the lowest legitimate brand-name option in the U.S. as of September 2026, and GoodRx now surfaces the same offer at retail pharmacies rather than a separate coupon.

For a fuller comparison, see /articles/cost-and-insurance/wegovy-savings-card/.

The Wegovy Savings Card path to $25

The Wegovy Savings Card is a Novo Nordisk copay assistance program. Eligible patients can pay as little as $25 per 28-day fill.

Eligibility:

• Commercial insurance that covers Wegovy with a copay
• U.S. resident
• Adult 18-plus
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government plan

How it works:

• Card pays up to $100 toward your copay per 1-month fill ($200 per 2-month fill, $300 per 3-month fill)
• The floor is $25; if your copay is above $125 you pay the excess
• Terms have changed more than once; the figures here were read from novocare.com on September 4, 2026

The math example:

• If your copay is $125, the card pays $100 and you pay $25.
• If your copay is $250, the card pays $100 and you pay $150.
• If your copay is $50, the card pays $25 and you pay $25 (because the floor is $25).

Novo does not publish how many card users reach the $25 floor; what you pay depends entirely on your plan's copay against the $100 monthly cap.

For the full how-to, see /articles/general-glp1/how-do-you-get-25-wegovy/.

Why Medicare and Medicaid patients pay more

Medicare. The 2003 Medicare Modernization Act excludes "agents when used for anorexia, weight loss, or weight gain" from Part D coverage, and under the standard benefit Part D plans may cover Wegovy only for cardiovascular risk reduction in patients with established heart disease. What changed in 2026 is the Medicare GLP-1 Bridge: from July 1, 2026 through December 31, 2027, eligible Part D beneficiaries with obesity pay $50 a month for any strength of the Wegovy pen or pill, with prior authorization (CMS; wegovy.com).

For most Medicare patients, the practical options are:

• The Medicare GLP-1 Bridge at $50 a month if you meet the CMS criteria (see the section below), or Novo self-pay at $199 to $349 a month for the pen (Medicare patients can use self-pay)
• Compounded semaglutide, median $197 for month 1 in September 2026
• Patient Assistance Program (qualifying low-income patients can apply)

Medicaid. Coverage varies by state. As of 2025, 16 state Medicaid programs covered GLP-1s for weight loss; California, New Hampshire, Pennsylvania and South Carolina ended that coverage in 2026, per healthinsurance.org. State Medicaid coverage typically requires BMI 30-plus and documentation of failed lifestyle interventions. Outside those states, Medicaid patients face the same cash-vs-compounded decision as Medicare patients.

The compounded semaglutide alternative

For patients who cannot afford brand-name Wegovy at any price tier (savings card, NovoCare, retail cash), compounded semaglutide is the most common alternative.

Pricing for compounded semaglutide:

• FormBlends compounded semaglutide: current price on the product page and in our price index
• Other telehealth providers: $88 to $299 for month 1, median $197; $149 to $437 by month 4, median $224 (FormBlends price index, September 3, 2026)
• Local 503A compounding pharmacies: not tracked in the index; ask for the all-in monthly price in writing

Important context:

• Compounded semaglutide is not FDA-approved.
• It is not interchangeable with brand-name Wegovy.
• It is drawn from a vial with a U-100 insulin syringe rather than delivered by a prefilled pen.
• It bypasses insurance, so there is no PA paperwork or formulary fight.
• The active ingredient is the same molecule as Wegovy (semaglutide).

When compounded makes financial sense:

• Your insurance does not cover Wegovy and you cannot afford $349 a month for the pen or $149 to $299 for the pill through Novo self-pay.
• You do not qualify for the savings card (Medicare, Medicaid).
• You want predictable monthly pricing without insurance paperwork.
• Compounded providers can offer dose flexibility (drawing different amounts) that brand-name pens do not.

When brand-name makes more sense:

• Your insurance covers Wegovy and the savings card brings you to $25 per fill.
• You strongly prefer FDA-approved medications.
• You qualify for the Patient Assistance Program (free).

For the full trade-off discussion, see /articles/glp1-hub/compounded-semaglutide-for-weight-loss-complete-guide-2026.

Wegovy vs Zepbound vs Ozempic on price

For patients shopping by price across the GLP-1 class:

Medication	List price	Cash low option	Insured + savings card	Compounded equivalent
Wegovy	$1,349.02/mo list; $675 from January 1, 2027	$199 then $349 pen; $149 to $299 pill (Novo self-pay)	$25	Compounded semaglutide, median $197 month 1 (September 2026)
Zepbound	Self-pay replaces list for most cash buyers	$299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg with a refill within 45 days) via LillyDirect or GoodRx pharmacies	$25	Compounded tirzepatide, median $299 month 1 (September 2026)
Ozempic	About $1,027/mo list (CNBC, February 2026); $675 from January 1, 2027	Retail; check NovoCare for current Ozempic offers	$25	Compounded semaglutide, median $197 month 1 (September 2026)

Zepbound's LillyDirect self-pay program ($299 to $449 by dose) and Wegovy's Novo self-pay program ($199 intro, then $349 for the pen) are now within about $100 of each other at maintenance doses, so the choice usually comes down to your plan's formulary and which molecule your clinician prefers.

For comparison guidance, see /articles/comparison/wegovy-vs-zepbound/.

How to lower your specific Wegovy cost in 2026

Five-step process to find the lowest price you qualify for:

Step 1: Verify your insurance coverage. Log into your member portal and search "semaglutide" or "Wegovy" in the formulary. Note tier, PA requirements, and copay.

Step 2: If covered, enroll in the Wegovy Savings Card. Visit the Wegovy website. Enroll. Bring the card to your first fill.

Step 3: If not covered, file a PA appeal. Have your provider submit BMI documentation, comorbidity records, and failed-alternative documentation.

Step 4: If appeal denied, evaluate NovoCare cash vs compounded. $349 a month for the brand-name pen after the intro offer (or $149 to $299 for the pill) vs a September 2026 median of $197 to $224 a month for compounded semaglutide. The gap has narrowed, and compounded is not FDA-approved.

Step 5: Apply for the Novo Nordisk Patient Assistance Program if low-income. Income at or below 400% of the federal poverty level ($63,840 for one person, $132,000 for a family of four under the 2026 HHS guidelines) with no coverage can qualify; confirm that Wegovy is on the current PAP product list before applying.

This sequence (insurance, then savings card, then appeal, then Novo self-pay, then compounded, then PAP, plus the Medicare Bridge for Part D patients) covers every legal lower-cost path for Wegovy in 2026.

Wegovy pill vs pen: self-pay price by dose (updated September 2026)

Novo Nordisk now publishes one self-pay price list for every Wegovy product, and it replaces the $499 figure that circulated in 2025. These prices come from the NovoCare Price Guide dated April 2026 and were confirmed on wegovy.com and novocare.com on September 4, 2026. A month is one box of four pens or one bottle of 30 tablets.

Product and dose	Self-pay price per month	Condition
Wegovy pen 0.25 mg and 0.5 mg	$199	First two fills only, new patients (no Wegovy fill in the prior 365 days per GoodRx), through December 31, 2026
Wegovy pen 0.25 mg to 2.4 mg	$349	Every dose after the intro offer
Wegovy HD pen 7.2 mg	$399	Same program
Wegovy pill 1.5 mg	$149	Ongoing
Wegovy pill 4 mg	$199	The $149 offer on 4 mg ended August 31, 2026
Wegovy pill 9 mg and 25 mg	$299	Ongoing

Two practical points. The pill's $149 entry price is now below the September 2026 median for compounded semaglutide ($197), which changes the cash-pay calculation that most of this article was written around. And the pen's $349 ongoing price is what a self-pay patient should compare against a savings-card copay: if your copay after the $100 card benefit is above $349, self-pay is cheaper.

Medicare now covers Wegovy for $50 a month through the GLP-1 Bridge (July 1, 2026 to December 31, 2027)

The Medicare section above described the law as it stood before July 2026. The statutory exclusion still exists, but CMS is now paying for weight-loss GLP-1s outside it. The Medicare GLP-1 Bridge, run by the CMS Innovation Center, gives eligible Part D beneficiaries access to Wegovy (pen and pill, all strengths), the Zepbound KwikPen and Foundayo for a $50 monthly copay from July 1, 2026 through December 31, 2027. The program was extended through 2027 because the BALANCE model is not launching that year (CMS provider page, last modified August 6, 2026).

• Cost: $50 a month. The Part D deductible does not apply, the $50 does not count toward the beneficiary's out-of-pocket total, and there is no low-income subsidy on it.
• Eligibility (CMS): age 18 or older with a BMI of 35 or higher; or a BMI of 30 or higher with heart failure, uncontrolled hypertension despite two antihypertensive medications, or chronic kidney disease stage 3a or above; or a BMI of 27 or higher with pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease, with BMI judged at the time GLP-1 therapy was started. Beneficiaries who already qualify for GLP-1 coverage through their Part D plan (for diabetes, for example) use that coverage instead.
• Process: prior authorization through a single central processor rather than your Part D plan.

For a Medicare patient with obesity, $50 a month beats every other route on this page, including Novo's own self-pay price.

Savings card math that is current: $25 floor, $100 monthly cap

The savings card section above was rewritten in September 2026 to match Novo's published terms: pay as little as $25, subject to a maximum savings of $100 per 1-month prescription, $200 per 2-month prescription, or $300 per 3-month prescription, for commercially insured patients whose plan covers Wegovy. The card applies to the pen (0.25 to 2.4 mg), Wegovy HD and the pill. Government beneficiaries are excluded.

Your plan's copay per month	Card pays	You pay	Cheaper alternative?
$50	$25	$25	No
$125	$100	$25	No
$250	$100	$150	Pill at $149 (1.5 mg) is about equal
$450	$100	$350	Self-pay pen at $349 is about equal
$600 (coinsurance)	$100	$500	Yes: self-pay pen $349 or pill $149 to $299
3-month fill, $600 copay	$300	$300 ($100 a month)	No

The break-even is simple: once your copay minus $100 exceeds $349, Novo's self-pay pen price wins, and no claim is filed against your deductible either way.

Annual cost scenarios: list vs self-pay vs pill vs Bridge

Twelve months of Wegovy in 2026, using only published prices as of September 4, 2026.

Route	Monthly	First-year total	Source
List price, 13 fills	$1,349.02	$17,537	NovoCare
Retail without an offer	About $1,643	About $19,716	GoodRx average retail
Self-pay pen, new patient	$199 x 2, then $349 x 10	$3,888	NovoCare Price Guide
Self-pay pen, existing patient	$349	$4,188	NovoCare Price Guide
Wegovy pill 1.5 mg	$149	$1,788	NovoCare Price Guide
Commercial insurance plus savings card, copay at or under $125	$25	$300 plus any deductible	novocare.com terms
Medicare GLP-1 Bridge	$50	$600	CMS
Compounded semaglutide at index medians	$197 month 1, $224 by month 4	About $2,600	FormBlends price index, September 3, 2026

What changes on January 1, 2027: the $675 list price

On February 24, 2026 Novo Nordisk said the U.S. list price of Wegovy (pen and pill), Ozempic and Rybelsus will fall to $675 a month on January 1, 2027, from about $1,350 for the Wegovy products and about $1,027 for the diabetes products (CNBC). This is a list-price change, not a self-pay change. Who it helps: insured patients whose plan charges coinsurance (30 percent of $675 is $203, against $405 today) and patients inside a deductible, who pay the negotiated rate until they meet it. Who it does not help much: self-pay patients, who already pay $149 to $349 through Novo's program, and Medicare Bridge patients at $50. If your plan covers Wegovy with coinsurance, the January 2027 change may cut your monthly cost roughly in half without any action on your part.

Patient assistance program income limits for 2026

Novo Nordisk's Patient Assistance Program uses the HHS poverty guidelines, which were updated for 2026. NovoCare's PAP page states the 2026 rules: uninsured patients qualify at or below 400 percent of the federal poverty level for all products except Ozempic (200 percent); uninsured applicants whose income falls within their state's Medicaid limits must show a Medicaid denial; uninsured patients are enrolled for 12 months; Medicare beneficiaries with drug coverage are no longer eligible for Ozempic through the PAP, and Part D patients may apply after October 15, 2026 for 2027. One caution: the PAP page we read on September 4, 2026 did not list Wegovy by name, so confirm that Wegovy is on the current product list before you start an application.

Household size	2026 poverty guideline	400 percent (PAP limit)	200 percent (Ozempic)
1	$15,960	$63,840	$31,920
2	$21,640	$86,560	$43,280
3	$27,320	$109,280	$54,640
4	$33,000	$132,000	$66,000

Add $5,680 to the guideline for each additional person (48 states and D.C.; Alaska and Hawaii use higher figures).

FAQ

How much does Wegovy cost without insurance?

Retail cash price without an offer averages about $1,643 per month (GoodRx, September 2026). Novo's self-pay price is $199 a month for the first two pen fills, then $349, or $149 to $299 for the pill. Compounded semaglutide had a September 2026 median of $197 for month 1.

How much does Wegovy cost with insurance?

Typically $25 to $500 per month depending on your plan. With the Wegovy Savings Card, eligible commercial-insured patients can pay as little as $25 per fill. Plans that exclude anti-obesity medications cover none of the cost.

Why is Wegovy so expensive?

Wegovy is a brand-name injectable manufactured by Novo Nordisk under patent. There is no generic version. List price reflects R&D costs, manufacturing, distribution, and Novo Nordisk's pricing strategy. The list price is $1,349.02 per package as of September 2026, and Novo has announced a cut to $675 effective January 1, 2027.

Is there a cheaper version of Wegovy?

Yes. The Wegovy pill at $149 a month (1.5 mg) is the cheapest brand-name option, and the pen is $199 for the first two fills, then $349. Compounded semaglutide, with a September 2026 month-1 median of $197, is the cheapest legitimate non-brand option.

How much is Wegovy at Walmart?

Walmart's cash price without an offer sits near the $1,643 retail average GoodRx reports. Ask the pharmacy to run Novo's self-pay offer instead: $199 to $349 for the pen or $149 to $299 for the pill. With insurance, Walmart processes the same negotiated rate as other major retail pharmacies.

Does Medicare cover Wegovy?

Since July 1, 2026, yes for eligible patients: the Medicare GLP-1 Bridge covers every strength of the Wegovy pen and pill for $50 a month through December 31, 2027, with prior authorization and BMI-based criteria set by CMS. Outside the Bridge, Part D covers Wegovy only for cardiovascular risk reduction in patients with established heart disease.

How do I get the $25 Wegovy price?

Enroll in the Wegovy Savings Card on the Wegovy website and use it alongside commercial insurance that already covers Wegovy. The card reduces eligible copays to as low as $25 per 28-day fill.

Is compounded semaglutide really cheaper than Wegovy?

Yes, by a large margin for cash-pay patients. Compounded semaglutide had a September 2026 median of $197 a month against about $1,643 for Wegovy at retail without an offer, though the gap to Novo's $349 self-pay pen price is much smaller. The trade-off is FDA approval status and the requirement to draw your own dose from a vial.

How much will Wegovy cost without coverage in 2026?

A new self-pay patient on the pen pays $199 for each of the first two fills and $349 after that, about $3,888 in the first year. The 1.5 mg pill at $149 a month is $1,788 a year. Retail without an offer is about $1,643 a month. Compounded semaglutide at the September 2026 medians ($197 month 1, $224 by month 4) runs roughly $2,600 a year.

Will the price of Wegovy go down?

Yes, at the list level. Novo Nordisk announced on February 24, 2026 that Wegovy, the Wegovy pill, Ozempic and Rybelsus will move to a $675 monthly list price on January 1, 2027 (CNBC). Self-pay prices are already below that figure, so the cut mostly helps insured patients who pay coinsurance or are inside a deductible.

Does Costco sell Wegovy cheaper?

On retail cash, Costco has historically been the lowest of the major chains, but the difference matters less now that Novo's self-pay price is the same at every participating pharmacy. Membership is required ($60 per year base, $120 executive). Costco's pricing covers cash-pay; insured pricing is similar across chains.

Can I split Wegovy doses to make a fill last longer?

No. Each Wegovy pen is dosed at a fixed amount per click. Patients cannot mathematically split a 2.4 mg pen into multiple smaller doses. With compounded semaglutide drawn from a vial, dose splitting is technically possible and is one reason some patients prefer the compounded format for budget reasons. Always follow your provider's dosing guidance.

How much does the Wegovy pill cost?

The Wegovy pill is $149 a month self-pay for the 1.5 mg strength, $199 for 4 mg (after the $149 offer ended August 31, 2026) and $299 for 9 mg and 25 mg, per the NovoCare Price Guide (April 2026) and wegovy.com on September 4, 2026. The list price is $1,349.02 per bottle. With commercial coverage the savings card applies to the pill too, so eligible patients pay as little as $25. Medicare Bridge patients pay $50.

Can you really get Wegovy for $25?

Yes, if three things are true: you have commercial insurance, your plan covers Wegovy, and your copay is $125 or less. Novo's card pays up to $100 a month toward the copay (September 2026 terms), so a $125 copay becomes $25 while a $250 copay becomes $150. Medicare, Medicaid, TRICARE and VA patients cannot use the card; Medicare patients with obesity may qualify for the $50 GLP-1 Bridge instead.

Is Wegovy cheaper than Zepbound or Ozempic?

Self-pay, the Wegovy pill at $149 is the cheapest branded GLP-1 for weight management as of September 2026. The Wegovy pen at $199 then $349 and the Zepbound KwikPen or vial at $299 to $449 are close at maintenance doses. Ozempic has no comparable Novo self-pay offer that we could verify and lists at about $1,027 per CNBC. On January 1, 2027 Wegovy and Ozempic both move to a $675 list price.

Sources

1. Novo Nordisk. Wegovy (semaglutide injection 2.4 mg) Prescribing Information, revised 2024.
2. Novo Nordisk. Wegovy wholesale acquisition cost announcement, May 2025.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
5. Novo Nordisk. NovoCare Pharmacy direct-to-patient program announcement and pricing, 2025.
6. Novo Nordisk. Wegovy Savings Card Terms and Conditions, 2026.
7. Mercer National Survey of Employer-Sponsored Health Plans. Coverage trends for anti-obesity medications, 2024.
8. Centers for Medicare and Medicaid Services. Medicare Part D coverage rules and 2024 updates for cardiovascular indications.
9. Kaiser Family Foundation. State Medicaid coverage of obesity medications: a 50-state survey, 2024.
10. American Diabetes Association. Standards of Care in Diabetes 2025. Diabetes Care. 2025;48(Suppl 1).
11. GoodRx Research. Pharmacy pricing data for GLP-1 medications, 2024 to 2025.
12. Novo Nordisk. What to pay for Wegovy, self-pay and savings offer pricing, read September 4, 2026. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
13. Novo Nordisk (NovoCare). Wegovy Savings Card eligibility and terms, read September 4, 2026. https://www.novocare.com/eligibility/wegovy-savings-card.html
14. Novo Nordisk (NovoCare). Wegovy Price Guide, US26NC00049, April 2026. https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
15. Novo Nordisk (NovoCare). Wegovy list price per package, read September 4, 2026. https://www.novocare.com/patient/medicines/wegovy.html
16. Novo Nordisk (NovoCare). Patient Assistance Program eligibility for 2026, read September 4, 2026. https://www.novocare.com/diabetes/help-with-costs/pap.html
17. GoodRx. Wegovy prices and self-pay offer, read September 4, 2026. https://www.goodrx.com/wegovy
18. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge model overview, read September 4, 2026. https://www.cms.gov/priorities/innovation/innovation-models/medicare-glp-1-bridge
19. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge: information for providers, page last modified August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
20. healthinsurance.org (Louise Norris). Does health insurance cover GLP-1 medications for weight loss?, updated August 20, 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
21. U.S. Department of Health and Human Services, ASPE. 2026 poverty guidelines. https://aspe.hhs.gov/poverty-guidelines
22. CNBC. Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50 percent, February 24, 2026. https://www.cnbc.com/2026/02/24/novo-nordisk-to-slash-wegovy-ozempic-us-list-prices-by-up-to-50percent.html
23. Eli Lilly. LillyDirect Zepbound self-pay pricing, read September 4, 2026. https://www.lilly.com/lillydirect/zepbound
24. FormBlends Research. Compounded GLP-1 Price Index, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. NovoCare and LillyDirect are services of their respective owners. Walmart, CVS, Walgreens, Costco, Sam's Club, GoodRx, and Mark Cuban Cost Plus Drugs are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.